A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia areata is a condition where the body's immune system mistakenly attacks hair follicles, causing hair to fall out in patches or completely. This trial is studying a once-daily tablet called upadacitinib to see how safe and effective it is at helping hair grow back in people with severe hair loss. The study is open to adults and young people aged 12 to 63 who have lost at least half of their scalp hair and have had no natural regrowth over the past six months. Around 1,500 people worldwide will take part. Most participants will receive the active study medicine, while some will receive a placebo (a dummy pill with no active ingredients). If you join, you will take one tablet daily for up to three years and attend regular hospital visits for health checks, blood tests, and hair assessments.
At a glance
What is this study about?
Alopecia areata happens when your immune system, which normally fights off infections, mistakenly targets your hair roots (follicles). This causes hair to fall out, most often on the scalp, but it can also affect eyebrows, eyelashes, and body hair. Severe hair loss can be deeply distressing and can have a major impact on self-confidence and daily life.
This clinical study is testing a medicine called upadacitinib. It belongs to a group of medicines that work by dialling down the specific immune signals that cause inflammation around the hair follicles. By calming this immune attack, the treatment aims to give hair follicles a chance to recover and start growing hair again.
Currently, treatments for severe alopecia areata are limited, and existing options do not work for everyone. Because upadacitinib is already approved for other immune conditions, doctors want to find out whether it can provide a reliable, long-term way to help people with alopecia regrow their hair safely.
Key takeaways
- Tests whether daily upadacitinib tablets can safely help hair regrow in severe alopecia areata.
- Open to adults and young people aged 12 to 63 with at least 50% scalp hair loss.
- Most participants receive the active medicine, but 1 in 5 will start on a dummy pill (placebo).
- Requires taking a daily tablet and attending regular hospital check-ups for up to three years.
- You can change your mind and leave the study at any time without affecting your NHS care.
Who may be eligible?
This study is looking for adults and teenagers aged between 12 and 63 who have been diagnosed with severe alopecia areata. To qualify, you must have lost at least 50% of the hair on your head. Your current period of hair loss must have started less than eight years ago, and you must not have had any natural hair regrowth in the last six months.
You will not be able to take part if your hair loss is caused by something other than typical alopecia areata. This includes male or female pattern baldness, hair thinning linked to stress, hair loss from tight hairstyles (traction alopecia), or scarring types of hair loss.
People with other active skin problems on the scalp, such as psoriasis, severe eczema, or fungal infections like ringworm, are also unable to join, as these conditions can make it difficult to clearly measure how well the study medicine is working.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged between 12 and 63 years old.
- You have lost at least half (50% or more) of the hair on your head.
- You have not noticed any natural hair regrowth in the past six months.
- Your current bout of hair loss began less than eight years ago.
- You do not have other scalp skin conditions such as psoriasis, severe eczema, or fungal infections.
What does participation involve?
Taking part involves taking one tablet by mouth once every day for up to 160 weeks (around three years). At the start, participants are placed into different groups by chance. About 4 out of 5 people will receive upadacitinib, while 1 out of 5 will receive a placebo (dummy pill). Depending on how your hair responds, your treatment group may be reviewed and adjusted at weeks 24 and 52.
You will need to visit a study clinic or hospital regularly throughout the trial. During these visits, doctors and nurses will check your overall health, examine your scalp, take routine blood and urine samples, and ask you to fill in short questionnaires about how you are feeling. After you take your final dose of study medicine, there will be a follow-up period of about 30 days to make sure you remain well.
Potential risks and benefits
Locations (272)
- Total Skin and Beauty Dermatology Center /ID# 259539Verified postcodeBirmingham, United States· Active not recruiting
- Duplicate_Advanced Research Associates - Glendale /ID# 259108Verified postcodeGlendale, United States· Completed
- Southwest Skin Specialists /ID# 258234Verified postcodePhoenix, United States· Completed
- Alliance Dermatology and Mohs Center /ID# 258111Verified postcodePhoenix, United States· Active not recruiting
- Johnson Dermatology Clinic /ID# 259103Verified postcodeFort Smith, United States· Active not recruiting
- Duplicate_JOSEPH RAOOF MD,INC /ID# 258031Verified postcodeEncino, United States· Completed
- First Oc Dermatology /ID# 259220Verified postcodeFountain Valley, United States· Recruiting
- University of California Irvine /ID# 259096Verified postcodeIrvine, United States· Active not recruiting
- Dermatology Research Associates /ID# 258033Verified postcodeLos Angeles, United States· Recruiting
- Stanford University School of Medicine - Redwood City /ID# 259542Verified postcodeRedwood City, United States· Completed
- Integrative Skin Science and Research /ID# 258114Verified postcodeSacramento, United States· Recruiting
- University of California Davis Health /ID# 258112Verified postcodeSacramento, United States· Recruiting
Common questions
What is a placebo?
A placebo looks just like the real medicine but contains no active ingredients. Researchers use it to compare results fairly and see if changes in hair growth are truly caused by upadacitinib.
Will I definitely get the active medicine?
At the start, there is an 80% chance (4 in 5) you will receive upadacitinib and a 20% chance (1 in 5) you will receive the placebo. Later in the study, participants on placebo may have the chance to switch to the active drug.
Can teenagers join this study?
Yes, young people aged 12 and over can take part, provided local regulations allow it and both the teenager and their parent or guardian agree.
Will taking part cost me anything?
No, the study medicine, tests, and medical visits are provided free of charge. Many trials also offer help with travel expenses to and from the clinic.
What happens if I want to stop taking part?
You are completely free to leave the study at any point. Deciding to withdraw will not affect your relationship with your doctor or the normal healthcare you receive.
How to find out more
ABBVIE CALL CENTER
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.